Overall survival analysis from the ALCYONE trial in patients with transplant ineligible NDMM

L: English
Watch Spanish version

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, María Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, discusses the overall survival analysis from the ALCYONE trial in patients with newly diagnosed, transplant ineligible multiple myeloma.

María Victoria Mateos talks about the results from the phase III, randomized ALCYONE study that was conducted in elderly patients with NDMM. She discusses the superiority of the drug regimens in terms of patient response rates and MRD-status rate in the study arms.